杭州昊鑫生物科技股份有限公司
標準會員 | 第2年

當前位置:杭州昊鑫生物科技股份有限公司>>MCE>> HY-P9907曲妥珠-單抗

曲妥珠-單抗

參  考  價:1600
具體成交價以合同協議為準
  • 型號

    HY-P9907

  • 品牌

    MCE

  • 廠商性質

    代理商

  • 所在地

    杭州市

規(guī)格

1mg 1600元 10000支可售

聯系方式:鄧女士查看聯系方式

更新時間:2024-06-27 17:02:15瀏覽次數:271次

聯系我時,請告知來自 制藥網
同類優(yōu)質產品更多>
CAS號 180288-69-1 產地 國產
規(guī)格 1mg 級別 化工級
證書 ISO系列證書
Trastuzumab 是一種人源化 IgG1 單克隆抗體,其以高親和力與 HER2 選擇性結合。Trastuzumab 可用于 HER2 陽性轉移性乳腺癌和 HER2 陽性胃癌的研究。

Trastuzumab (Synonyms: 曲妥珠-單抗; Anti-Human HER2, Humanized Antibody)

Trastuzumab 是一種人源化 IgG1 單克隆抗體,其以高親和力與 HER2 選擇性結合。Trastuzumab 可用于 HER2 陽性轉移性乳腺癌和 HER2 陽性胃癌 的研究。

生物活性

Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.


IC50 & Target[1]

HER2


體外研究(In Vitro)

Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a consequence of Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets[1]. Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for antibody-dependent cytotoxicity[2]. The presence of Trastuzumab IgG significantly increases killing of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1[3].


體內研究(In Vivo)

Trastuzumab treatment of mouse xenograft models results in marked suppression of tumor growth. When given in combination with standard cytotoxic chemotherapeutic agents, Trastuzumab treatment generally results in statistically superior antitumor efficacy compared with either agent given alone[1]. Trastuzumab causes a significant growth inhibition of the outgrowth of macroscopic JIMT-1 xenograft tumors in both nude and SCID mice[3].


Clinical Trial

NCT NumberSponsorConditionStart DatePhase
NCT04158258Hoffmann-La Roche|Latin American Cooperative Oncology Group
Breast Cancer
February 21, 2020
NCT02774681Northwestern University|Pfizer|National Cancer Institute (NCI)
Breast Carcinoma Metastatic in the Brain|Estrogen Receptor Negative|HER2+Neu Negative|HER2+Neu Positive|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer
August 31, 2016Phase 2
NCT03493854Hoffmann-La Roche
Early Breast Cancer
June 14, 2018Phase 3


分子量:145531.50


Formula:C6470H10012N1726O2013S42


CAS 號:180288-69-1


中文名稱:曲妥珠-單抗;曲妥-單抗;群司珠-單抗


儲存方式;Please store the product under the recommended conditions in the Certificate of Analysis.


參考文獻

  • [1]. Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70.

    [2]. Hudis CA, et al. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51.

    [3]. Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6(7):2065-72.









注:產品僅用于科研

會員登錄

×

請輸入賬號

請輸入密碼

=請輸驗證碼

收藏該商鋪

X
該信息已收藏!
標簽:
保存成功

(空格分隔,最多3個,單個標簽最多10個字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時間回復您~
在線留言